Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma A253 xenografts

Neoplasia

Volumn 10, Issue 8, 2008, Pages 857-865

  Bhattacharya, Arup ^a   Tóth, Károly ^a   Durrani, Farukh A ^a   Cao, Shousong ^a   Slocum, Harry K ^a   Chintala, Sreenivasulu ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE; CD31 ANTIGEN; CYSTEINE DERIVATIVE; IRINOTECAN; METHYLSELENOCYSTEINE; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG EFFICACY; DRUG INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR CELL; XENOGRAFT;

EID: 48249091370     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08424     Document Type: Article

References (34)

1. Fukumura D and Jain RK (2007). Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74, 72-84.
2. Ackerstaff E, Artemov D, Gillies RJ, and Bhujwalla ZM (2007). Hypoxia and the presence of human vascular endothelial cells affect prostate cancer cell invasion and metabolism. Neoplasia 9, 1138-1151.
3. Mikhaylova M, Mori N, Wildes FB, Walczak P, Gimi B, and Bhujwalla ZM (2008). Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia 10, 380-389.
4. Cairns R, Papandreou I, and Denko N (2006). Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4, 61-70.
5. Bhattacharya A, Toth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, and Rustum YM (2004). Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res 10, 8005-8017.
6. Cao S, Durrani FA, and Rustum YM (2004). Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 10, 2561-2569.
7. Bhattacharya A, Seshadri M, Oven SD, Toth K, Vaughan MM, and Rustum YM (in press). Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res.
8. Fakih M, Pendyala L, Brady W, Smith P, Ross M, Creaven P, Badmaev V, Prey JD, and Rustum YM (2007). A phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemother Pharmacol. DOI 10.1007/s00280-007-0631-4, E-pub ahead of print.
9. Durand RE and Olive PL (1997). Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 5, 213-219.
10. Marcu L, Bezak E, and Olver I (2006). Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach. Phys Med Biol 51, 3625-3637.
11. Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, and Wilson WR (2004). Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Res 64, 736-742.
12. Denny WA (2000). The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol 1, 25-29.
13. Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, Mills GM, and Gandara DR (2005). Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 23, 9097-9104.
14. Brown JM (1993). SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67, 1163-1170.
15. Dorie MJ, Kovacs MS, Gabalski EC, Adam M, Le QT, Bloch DA, Pinto HA, Terris DJ, and Brown JM (1999). DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia 1, 461-467.
16. Shin HJ, Kim JY, Yoo CW, Roberts SA, Lee S, Choi SJ, Lee HY, Lee DH, Kim TH, and Cho KH (2008). Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine. J Cancer Res Clin Oncol 134, 397-404.
17. Seshadri M, Mazurchuk R, Spernyak JA, Bhattacharya A, Rustum YM, and Bellnier DA (2006). Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia 8, 534-542.
18. Weitman S, Mangold G, Marty J, Dexter D, Hilsenbeck S, Rake J, Juniewicz P, and Von Hoff D (1999). Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 43, 402-408.
19. Galmarini FC, Galmarini CM, Sarchi MI, Abulafia J, and Galmarini D (2007). Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer. Microcirculation 7, 405-410.
20. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, and Sculier JP (2002). The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87, 694-701.
21. Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Coates S, Simmons T, Neefe J, and von Roemeling R (1997). Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 8, 363-367.
22. Gatineau M, Rixe O, and Chevalier TL (2005). Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study. Clin Lung Cancer 6, 293-298.
23. Johnson CA, Kilpatrick D, von Roemeling R, Langer C, Graham MA, Greenslade D, Kennedy G, Keenan E, and O'Dwyer PJ (1997). Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol 15, 773-780.
24. Lara PN Jr, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, et al. (2003). Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a California Cancer Consortium phase I and molecular correlative study. Clin Cancer Res 9, 4356-4362.
25. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, and Kris MG (1997). Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 8, 1269-1271.
26. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, et al. (2005). Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23, 79-87.
27. Senan S, Rampling R, Graham MA, Wilson P, Robin H Jr, Eckardt N, Lawson N, McDonald A, von Roemling R, Workman P, and Kaye SB (1997). Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3, 31-38.
28. Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, and Rustum YM (2006). A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clin Cancer Res 12 (4), 1237-1244.
29. Miki K, Xu M, Gupta A, Ba Y, Tan Y, Al-Refaie W, Bouvet M, Makuuchi M, Moossa AR, and Hoffman RM (2001). Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res 61, 6805-6810.
30. Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, Treszezamsky A, Chon BH, Feng Z, Gu Y, et al. (2008). Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res 68 (1), 257-265.
31. Huxham LA, Kyle AH, Baker JH, McNicol KL, and Minchinton AI (2008). Exploring vascular dysfunction caused by tirapazamine. Microvasc Res 75, 247-255.
32. Huxham LA, Kyle AH, Baker JH, McNicol KL, and Minchinton AI (2006). Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother Oncol 78 (2), 138-145.
33. Cardenas-Navia LI, Secomb TW, and Dewhirst MW (2007). Effects of fluctuating oxygenation on tirapazamine efficacy: theoretical predictions. Int J Radiat Oncol Biol Phys 67, 581-586.
34. Holben DH and Smith AM (1999). The diverse role of selenium within selenoproteins: a review. J Am Diet Assoc 99, 836-843.